During a meeting between members of the FDA and representatives of US drug company Richardson-Merrell, Dr. Francis Kelsey from the FDA specifically asked Merrell if they had any knowledge on the influence of Thalidomide on unborn babies. Dr. Kelsey was in charge of the approval process for Thalidomide at the FDA. Merrell was pressing the FDA for permission.